|
|
|
||
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(I.R.S. Employer
Identification No.) |
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
|
The
|
November 9, 2023
|
|
/s/ Steven C. Quay, M.D., Ph.D. |
Steven C. Quay, M.D., Ph.D.
President and Chief Executive Officer |
Document And Entity Information |
Nov. 09, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | Atossa Therapeutics, Inc. |
Document, Type | 8-K |
Document, Period End Date | Nov. 09, 2023 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-35610 |
Entity, Tax Identification Number | 26-4753208 |
Entity, Address, Address Line One | 107 Spring Street |
Entity, Address, City or Town | Seattle |
Entity, Address, State or Province | WA |
Entity, Address, Postal Zip Code | 98104 |
City Area Code | 206 |
Local Phone Number | 588-0256 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity, Emerging Growth Company | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | ATOS |
Security Exchange Name | NASDAQ |
Amendment Flag | false |
Entity, Central Index Key | 0001488039 |
&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 32&E799!YDAD! #/ M P $P @ &9$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" #C$P ! end
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